ClinicalTrials.gg
CompletedNCT03483649Updated May 11, 2022

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

A Phase 1 interventional study of HLX04 and US-Avastin® in Healthy Male Subjects, sponsored by Shanghai Henlius Biotech. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2017, 9 years ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Apr 2017, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is a Phase I, randomized, double blind, IV, single dose, 4-arm parallel study to compare the PK, and to evaluate the safety, tolerability and immunogenicity of HLX04, US Avastin®, EU Avastin®, and CN Avastin® in healthy male subjects.

Read the detailed description

A total of 188 evaluable male subjects are required. Taking into account a dropout rate of approximately 10%, a total of 208 healthy male subjects who meet the required entry criteria will be randomly assigned to one of four treatment groups in a 1:1:1:1 ratio to receive a single IV infusion of HLX04, EU Avastin® or US Avastin®. The first 8 subjects (with at least 2 subjects receiving HLX04) will be dosed as a maximum of 1 subject per day. Prior to administration of study drug to the next subject, the safety findings of the preceding subject must be reviewed by the Principal Investigator. Each subject will be required to remain in the study center for 96 hours after dosing (overnight) for safety evaluation. After the first 8 subjects are evaluated and the experimental drug deemed safe, the Principal Investigator will decide the continuous enrollment in the four parallels according to the Phase I clinical trial unit capability.

The duration of participation for each subject is expected to be approximately120 days starting with a 21 day screening period, followed by administration of study drug and a 99 day follow up period.

After the follow up visit on Day 99, subjects who are confirmed positive for anti drug antibody (ADA) will be followed for 12 months after study drug administration or until 2 consecutive samples are tested negative for ADA.

The start of study is considered the date of the first subject providing informed consent and the end of study will be the last subject's last scheduled visit (Day 99 or early termination). Additional follow up visits for subjects who are positive for ADAs or have ongoing/resolving adverse events (AEs) will be conducted and recorded separately.

Subjects who meet all eligibility criteria and have signed the informed consent form (ICF) will be admitted to the Phase I clinical trial unit the day prior to dosing (Day 1) and will be discharged 96 hours postdose on Day 5. Then after, subjects will be followed up and continue participation in the study on an outpatient basis for further safety assessments, for blood sampling for PK and to test for ADA and neutralizing ADA (NADA) at selected visits.

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 133 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to comply with the restrictions for this study (see Section 4.3.3).
  2. Subjects who are able and willing to give written .
  3. Subjects who are willing to comply with the study restrictions from screening until end of study.
  4. Adult males aged 18 to 50 years inclusive and between 19 and 26 kg/m2 and body weight ≥ 50 kg and ≤ 80 kg.
  5. Subjects who are non smokers or have not used tobacco or nicotine containing products for at least 3 months preceding screening and have less than 5 cigarettes per day smoking history. Subjects must agree to refrain from smoking during days of confinement at the study center.
  6. Subjects negative for surface antigen, virus antibody, Treponema pallidum antibody, and antibody tests.
  7. Subjects negative for urine drug screen and alcohol tests.
  8. Subjects determined healthy by medical history, physical examination, laboratory tests, 12 lead (ECG), and chest X ray, without any abnormality judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. History of gastrointestinal, endocrine, pulmonary, hepatic, renal, psychiatric, neurological, cardiovascular, hematological, and metabolic (including known diabetes mellitus) disease or disorder considered as significant by the Investigator.
  2. History of any cancer, lymphoma, or leukemia, except basal cell carcinoma of skin after localized cancer is removed.
  3. History or current atopic allergy, or allergic reactions including known or suspected clinically relevant drug hypersensitivity to any component of the study drug formulations or comparable drugs.
  4. Any disorder that, in the Investigator's opinion, may interfere with the safety of the subject and the study procedures and evaluations.
  5. Blood loss or blood donation (including blood components donation) ≥ 400 mL or blood transfusion within 3 months before screening; blood loss or blood donation (including blood components donation) ≥ 200 mL within 1 months before screening.
  6. Surgery within the past 8 weeks or surgery planned during the study duration.
  7. Poor oral hygiene that may require surgical intervention during the study or any planned dental interventions during the study duration.
  8. within 4 weeks prior to screening or intention to receive live virus vaccination during the study until the final follow up visit.
  9. History of prior exposure to bevacizumab or any anti VEGF or anti VEGF receptor (VEGFR) monoclonal antibodies or proteins (e.g., aflibercept, ramucirumab, lapatinib, and sunitinib).
  10. Prior exposure to any other monoclonal antibody within 12 months of study drug administration.
  11. Use of any investigational drug in any clinical study within the 3 months prior to first dose administration in this study; or remains on follow up of any clinical study.
  12. Any intake of a non steroidal anti inflammatory drug (NSAID) including any dose of aspirin in the last 14 days. NSAIDs are not allowed for the duration of the study. Paracetamol is allowed for pain control if required.
  13. Intake of prescribed or over the counter drugs within 28 days of study drug administration or herbal drugs or dietary supplements within 28 days prior to study drug administration.
  14. Any persons who are:

    • An employee of the Principal Investigators, study centers, contract research organization (CRO) or the Sponsor.
    • A relative of an employee of the study centers, the Investigators, CRO or the Sponsor.
  15. Abnormal with clinical significance judged by the Investigator.
  16. Abnormal serum Immunoglobulin G with clinical significance judged by the Investigator.
  17. Confirmed positive ADA at screening.
  18. Occurrence of acute disease during screening or predose, e.g., acute hepatitis, acute diarrhea.
  19. Intake of any product containing alcohol within 24 hours of study drug administration.
  20. Subjects with relevant family history of hypertension or abnormal blood pressure at screening or admission to the study center (Day 1):

    • Systolic blood pressure > 140 mmHg
    • Diastolic blood pressure > 90 mmHg.
  21. Any inherited predisposition to bleeding or to thrombosis or history of non traumatic hemorrhage (i.e., requiring medical intervention), thromboembolic event or any condition which may increase bleeding risk including clotting disorders, thrombocytopenia ( count \< 100000/µL) or an (INR) higher than 1.5.
  22. Any clinically significant infection ongoing at screening or admission to the Phase I clinical trial unit.
  23. Total cholesterol > 1.5× or fasting glucose abnormality with clinical significance at screening or admission.
  24. History of alcohol abuse or a positive alcohol breath test, history of drug abuse or positive urine drug screen.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    HLX04

    Drug: HLX04

  • Active comparator
    United States (US) Avastin®

    Drug: US-Avastin®

  • Active comparator
    European Union (EU) Avastin®

    Drug: EU-Avastin®

  • Active comparator
    China (CN) Avastin®

    Drug: CN-Avastin®

Interventions

  • DrugHLX04

    HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.

  • DrugUS-Avastin®

    US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.

  • DrugEU-Avastin®

    EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.

  • DrugCN-Avastin®

    CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.

06

What researchers measure

Primary outcomes

  1. AUC(0-t)

    Area under the concentration time curve of the analyte in serum over the time interval from 0 to the last quantifiable concentration at time "t" \[AUC(0-t)\]

    Time frame: from 0 to day 99

  2. AUC(0-∞)

    Area under the concentration time curve of the analyte in serum over the time interval from 0 extrapolated to infinity \[AUC(0-∞)\]

    Time frame: from 0 to day 99

Secondary outcomes

  1. Cmax

    Maximum measured concentration of the analyte in serum (Cmax)

    Time frame: from 0 to day 99

  2. TEAE and SAE

    Treatment emergent adverse events and serious adverse events

    Time frame: from 0 to day 99

  3. tmax

    • Time from dosing to maximum measured concentration (tmax)

    Time frame: from 0 to day 99

  4. t1/2

    • Terminal half life of the analyte in serum (t1/2)

    Time frame: from 0 to day 99

  5. λz

    • Terminal elimination rate constant (λz)

    Time frame: from 0 to day 99

  6. CL

    • Total clearance of the analyte in serum following IV infusion (CL)

    Time frame: from 0 to day 99

  7. Vss

    • Volume of distribution at steady state (Vss)

    Time frame: from 0 to day 99

  8. Vz

    • Volume of distribution during the terminal phase λz following an intravascular dose (Vz)

    Time frame: from 0 to day 99

  9. Immunogenicity

    Incidence of anti drug antibodies (ADAs), including neutralizing ADAs (NADAs)

    Time frame: from 0 to day 99

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
08

References and documents

Publications

  • Zhu X, Qian H, Sun J, Wu M, Yu C, Ding Y, Zhang X, Chai K, Li X. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2021 Sep;88(3):465-474. doi: 10.1007/s00280-021-04297-z. Epub 2021 Jun 4. PubMed 34086067 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Oct 2017, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Mar 30, 2018
StartActual
Apr 21, 2017
Primary completionActual
Oct 29, 2017
CompletionActual
Oct 29, 2017
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03483649
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Apr 21, 2017
Primary completion
Oct 29, 2017
Completion
Oct 29, 2017
Last update
May 11, 2022

Study contacts

Yanhua Ding, M.D.
principal investigator · The First Hospital of Jilin University
Chen Yu, M.D.
principal investigator · Shanghai Xuhui Central Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX04

Start the discussion